蜜芽传媒

Coverage of the Science, Innovation and Technology committee session on life sciences investment following Merck's (MSD in Europe) decision to halt its 拢1bn UK expansion, with evidence from MSD's managing director for UK and Ireland, Ben Lucas, UK president at AstraZeneca, Tom Keith-Roach, Dr Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, health minister Dr Zubir Ahmed and science minister Lord Vallance of Balham, from Tuesday 16 September.